1,3,3-Trimeth­yl-6'-(4-phenyl­piperazin-1-yl)-2,3-dihydro­spiro­[1H-indole-2,3'-3H-naphth[2,1-b][1,4]oxazine]

The title compound, C₃₂H₃₂N₄O, a spiro­oxazine modified with a fused phen­yl-piperazin­yl-naphthalene moiety, has been characterized by X-ray crystallographic techniques. The piperazine ring is in a chair conformation, while the oxazine and pyrrolidine rings adopt envelope conformations.

7-Methyl-1-(β-D-erythro-pento­furan­osyl)-1H-benzimidazol-2(3H)-one

The title nucleoside, C₁₃H₁₆N₂O₅, was prepared and characterized by X-ray crystallographic tech­niques. The crystal structure determination reveals that the furan­ose ring adopts a C2′-endo conformation, while the orientation of the benz­imidazole moiety with respect to the sugar moiety is mid-anti. The crystal structure is stabilized by intermolecular O—H...O and N—H...O hydrogen bonds.

An asymmetric bi­phenyl compound: 3-chloro-4,4'-di­methoxy­bi­phenyl

The asymmetric bi­phenyl title compound, C₁₄H₁₃ClO₂, exhibits a significant twist of ca 30° about the central C-C bond.

8-Bromo-6-chloro­-1',3',3',5'-tetra­meth­ylspiro­[2H-1-benzopyran-2,2'-indoline]

In the title compound, C₂₀H₁₉BrClNO, the pyrrolidine ring adopts an envelope conformation, while the pyran ring is in a twist-boat form.